Barbara Sleight

2.4k total citations · 1 hit paper
23 papers, 1.5k citations indexed

About

Barbara Sleight is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Hematology. According to data from OpenAlex, Barbara Sleight has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Public Health, Environmental and Occupational Health, 14 papers in Oncology and 9 papers in Hematology. Recurrent topics in Barbara Sleight's work include Acute Lymphoblastic Leukemia research (15 papers), CAR-T cell therapy research (12 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Barbara Sleight is often cited by papers focused on Acute Lymphoblastic Leukemia research (15 papers), CAR-T cell therapy research (12 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Barbara Sleight collaborates with scholars based in United States, Germany and Italy. Barbara Sleight's co-authors include Erik Vandendries, Hagop M. Kantarjian, Anjali S. Advani, Matthias Stelljes, Daniel J. DeAngelo, Susan O’Brien, Wendy Stock, Michaela Liedtke, Nicola Gökbuget and Tao Wang and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Barbara Sleight

23 papers receiving 1.4k citations

Hit Papers

Inotuzumab Ozogamicin versus Standard Therapy for Acute L... 2016 2026 2019 2022 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
    2016 869 citations Hagop M. Kantarjian, Daniel J. DeAngelo et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Sleight United States 10 879 874 618 270 226 23 1.5k
Richard Champlin United States 19 428 0.5× 638 0.7× 1.1k 1.7× 161 0.6× 118 0.5× 52 1.7k
C. Michel Zwaan Netherlands 18 503 0.6× 449 0.5× 554 0.9× 104 0.4× 158 0.7× 34 1.2k
ER van Wering Netherlands 17 1.2k 1.4× 264 0.3× 1.0k 1.6× 357 1.3× 360 1.6× 17 1.7k
Thibaut Leguay France 21 1.3k 1.4× 461 0.5× 1.2k 2.0× 232 0.9× 482 2.1× 61 1.9k
Paul Cannell Australia 18 225 0.3× 373 0.4× 519 0.8× 295 1.1× 102 0.5× 55 1.1k
F. R. Appelbaum United States 14 245 0.3× 287 0.3× 552 0.9× 273 1.0× 94 0.4× 25 1.1k
Musa Yılmaz United States 25 641 0.7× 553 0.6× 1.5k 2.4× 146 0.5× 118 0.5× 149 2.0k
Peter Duggan Canada 18 198 0.2× 455 0.5× 841 1.4× 287 1.1× 49 0.2× 106 1.4k
Susan McKenzie United States 14 439 0.5× 342 0.4× 766 1.2× 158 0.6× 63 0.3× 19 1.2k
Clare Rowntree United Kingdom 18 1.1k 1.3× 309 0.4× 681 1.1× 245 0.9× 708 3.1× 56 1.7k

Countries citing papers authored by Barbara Sleight

Since Specialization
Citations

This map shows the geographic impact of Barbara Sleight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Sleight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Sleight more than expected).

Fields of papers citing papers by Barbara Sleight

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Sleight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Sleight. The network helps show where Barbara Sleight may publish in the future.

Co-authorship network of co-authors of Barbara Sleight

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Sleight. A scholar is included among the top collaborators of Barbara Sleight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Sleight. Barbara Sleight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kantarjian, Hagop M., Wendy Stock, Ryan D. Cassaday, et al.. (2021). Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research. 27(10). 2742–2754. 29 indexed citations
2.
Cortes, Jörge E., Hervé Dombret, Akil Merchant, et al.. (2019). Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials. Future Oncology. 15(31). 3531–3545. 38 indexed citations
3.
Brivio, Erica, Marta López‐Yurda, Cristina Díaz de Heredia, et al.. (2019). A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study. Blood. 134(Supplement_1). 2629–2629. 7 indexed citations
4.
Jabbour, Elias, Anjali S. Advani, Matthias Stelljes, et al.. (2019). Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology. 94(4). 408–416. 12 indexed citations
5.
Fujishima, Naohito, Toshiki Uchida, Yasushi Onishi, et al.. (2019). Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. International Journal of Hematology. 110(6). 709–722. 8 indexed citations
6.
7.
Jabbour, Elias, Daniel J. DeAngelo, Matthias Stelljes, et al.. (2018). Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE. Cancer. 124(8). 1722–1732. 44 indexed citations
8.
Kantarjian, Hagop M., Wendy Stock, Ryan D. Cassaday, et al.. (2018). Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials. Blood. 132(Supplement 1). 2699–2699. 3 indexed citations
9.
Cortes, Jörge E., Hervé Dombret, Akil Merchant, et al.. (2018). Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.. Journal of Clinical Oncology. 36(15_suppl). TPS7073–TPS7073. 5 indexed citations
10.
Kantarjian, Hagop M., Daniel J. DeAngelo, Matthias Stelljes, et al.. (2017). Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study. Blood. 130. 2574–2574. 5 indexed citations
11.
Kantarjian, Hagop M., Daniel J. DeAngelo, Anjali S. Advani, et al.. (2017). Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. The Lancet Haematology. 4(8). e387–e398. 138 indexed citations
12.
Kantarjian, Hagop M., Daniel J. DeAngelo, Matthias Stelljes, et al.. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine. 375(8). 740–753. 869 indexed citations breakdown →
13.
DeAngelo, Daniel J., Elias Jabbour, Matthias Stelljes, et al.. (2016). Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy.. Journal of Clinical Oncology. 34(15_suppl). 7028–7028. 6 indexed citations
14.
Advani, Anjali S., Elias Jabbour, Matthias Stelljes, et al.. (2016). Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase. Blood. 128(22). 5188–5188. 2 indexed citations
15.
Haluska, Paul, Uta Dirksen, Arkadiusz Z. Dudek, et al.. (2012). OR10-5 Phase I study of figitumumab and pegvisomant in patients with advanced solid tumors. Growth Hormone & IGF Research. 22. S27–S27. 1 indexed citations
16.
Yin, Donghua, et al.. (2012). Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin‐Like Growth Factor 1 Receptor, in Healthy Participants. The Journal of Clinical Pharmacology. 53(1). 21–28. 13 indexed citations
17.
18.
Thayu, Meena, Robert S. Baltimore, Barbara Sleight, Miguel Reyes‐Múgica, & Peter J. Hotez. (1999). CDC GROUP IV c-2 BACTEREMIA IN A CHILD WITH RECURRENT ACUTE MONOBLASTIC LEUKEMIA. The Pediatric Infectious Disease Journal. 18(4). 397–398. 7 indexed citations
19.
Varelas, Panayiotis N., Barbara Sleight, Henry M. Rinder, Gordon Sze, & Laura R. Ment. (1998). Stroke in a Neonate Heterozygous for Factor V Leiden. Pediatric Neurology. 18(3). 262–264. 20 indexed citations
20.
Sleight, Barbara, et al.. (1994). S-cells from a highly N-myc-amplified neuroblastoma are tumorigenic in nude mice.. PubMed. 13(6A). 2031–6. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Champlin Breakdown of academic impact, for papers by C. Michel Zwaan Breakdown of academic impact, for papers by ER van Wering Breakdown of academic impact, for papers by Thibaut Leguay Breakdown of academic impact, for papers by Paul Cannell Breakdown of academic impact, for papers by F. R. Appelbaum Breakdown of academic impact, for papers by Musa Yılmaz Breakdown of academic impact, for papers by Peter Duggan Breakdown of academic impact, for papers by Susan McKenzie Breakdown of academic impact, for papers by Clare Rowntree
Rankless by CCL
2026